Skip to main content
SPRC
NASDAQ Life Sciences

SciSparc Subsidiary NeuroThera Labs Receives Conditional TSX Approval for CliniQuantum Acquisition, Amends Terms

Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
8
Price
$9.24
Mkt Cap
$6.048M
52W Low
$2.98
52W High
$80.1
Market data snapshot near publication time

Summary

SciSparc's subsidiary, NeuroThera Labs, received conditional TSX regulatory approval for its acquisition of CliniQuantum, a deal valued at over $9 million, and amended the purchase agreement to include a $0.05 floor price for earn-out shares and extend the closing date.


Key Events

  • Conditional Regulatory Approval Received

    NeuroThera Labs, SciSparc's subsidiary, received conditional regulatory approval from the TSX Venture Exchange for its acquisition of a 54% interest in CliniQuantum Ltd.

  • Significant Acquisition Value

    The acquisition is valued at approximately $9.46 million, which is substantially larger than SciSparc's current market capitalization.

  • Amendment to Share Purchase Agreement

    The Share Purchase Agreement was amended to include a minimum deemed price of $0.05 per common share for NeuroThera shares issued in connection with earn-out payments, a requirement from the TSX Venture Exchange.

  • Closing Date Extended

    The outside date for completing the transaction has been extended from April 30, 2026, to June 1, 2026, to allow for additional time to satisfy closing conditions.


Analysis

This 6-K provides an update on SciSparc's subsidiary NeuroThera Labs' acquisition of a 54% stake in CliniQuantum. The conditional regulatory approval from the TSX Venture Exchange is a significant step towards closing this acquisition, which is valued at approximately $9.46 million, substantially exceeding SciSparc's current market capitalization. The amendment to the Share Purchase Agreement, including a $0.05 floor price for future earn-out share issuances and an extension of the closing date to June 1, 2026, provides crucial details on the deal's structure and timeline.

At the time of this filing, SPRC was trading at $9.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $2.98 to $80.10. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SPRC - Latest Insights

SPRC
May 29, 2026, 7:40 AM EDT
Filing Type: 6-K
Importance Score:
8
SPRC
May 28, 2026, 8:40 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
SPRC
May 11, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
SPRC
Apr 29, 2026, 4:20 PM EDT
Filing Type: 20-F
Importance Score:
9
SPRC
Mar 16, 2026, 8:21 AM EDT
Source: Reuters
Importance Score:
7
SPRC
Mar 12, 2026, 4:41 PM EDT
Filing Type: 6-K
Importance Score:
8
SPRC
Mar 12, 2026, 7:55 AM EDT
Source: GlobeNewswire
Importance Score:
7
SPRC
Mar 10, 2026, 9:28 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
SPRC
Mar 02, 2026, 8:08 AM EST
Filing Type: 6-K
Importance Score:
9
SPRC
Feb 17, 2026, 5:27 PM EST
Filing Type: F-3
Importance Score:
9